Literature DB >> 26813950

Prostate cancer: Testosterone-guided ADT for prostate cancer.

Tsutomu Nishiyama1, Tatsuhiko Hoshii1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26813950     DOI： 10.1038/nrurol.2016.9

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Toward excellence in testosterone testing: a consensus statement.

Authors:  William Rosner; Hubert Vesper
Journal:  J Clin Endocrinol Metab       Date:  2010-10       Impact factor: 5.958

2.  Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.

Authors:  Michael G Oefelein
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making.

Authors:  M G Oefelein; A Feng; M J Scolieri; D Ricchiutti; M I Resnick
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

4.  Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

Authors:  Juan Morote; Anna Orsola; Jacques Planas; Enrique Trilla; Carles X Raventós; Lluís Cecchini; Roberto Catalán
Journal:  J Urol       Date:  2007-08-14       Impact factor: 7.450

5.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

6.  Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.

Authors:  Saroj Niraula; Arnoud J Templeton; Francisco E Vera-Badillo; Anthony M Joshua; Srikala S Sridhar; Peter W Cheung; Paul M Yip; Anna Dodd; Zoann Nugent; Ian F Tannock
Journal:  Prostate       Date:  2015-11-02       Impact factor: 4.104

7.  Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.

Authors:  Apurba S Pathak; Judy S Pacificar; Charles E Shapiro; Stephen G Williams
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

8.  Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.

Authors:  Laurence Klotz; Chris O'Callaghan; Keyue Ding; Paul Toren; David Dearnaley; Celestia S Higano; Eric Horwitz; Shawn Malone; Larry Goldenberg; Mary Gospodarowicz; Juanita M Crook
Journal:  J Clin Oncol       Date:  2015-03-02       Impact factor: 44.544

9.  Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer.

Authors:  Fumio Ishizaki; Tsutomu Nishiyama; Takashi Kawasaki; Yoshimichi Miyashiro; Noboru Hara; Itsuhiro Takizawa; Makoto Naito; Kota Takahashi
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.